{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:58:07Z","timestamp":1778201887362,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pegylated liposomal doxorubicin (PLD)-induced hand-foot syndrome (HFS) frequently lowers the quality of life of ovarian cancer patients. Wrist and ankle cooling, having a limited preventive effect, has been the commonest supportive HFS care. In this study, we retrospectively assessed the primary preventive effect of a combination of regional cooling and oral dexamethasone therapy (cooling\u2009+\u2009oral Dex) on HFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is a single-arm retrospective, observational study. Recurrent ovarian cancer patients were administered PLD\u2009\u00b1\u2009bevacizumab. We retrospectively examined the efficacy of hands and feet cooling (from the start of PLD to the end)\u2009+\u2009oral Dex (day 1\u20135: 8\u00a0mg\/day, day 6, 7: 4\u00a0mg\/day) for primary HFS prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study included 74 patients. The initial dose of PLD was 50\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and 40\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      for 32 (43.2%) and 42 (56.8%) patients, respectively. HFS of Grade\u2009\u2265\u20092 and Grade\u2009\u2265\u20093 developed in five (6.8%) and one (1.4%) patient(s), respectively. The incidence of\u2009\u2265\u2009Grade 2 and\u2009\u2265\u2009Grade 3 HFS was much lower than those reported in previous studies. Dose reduction was required in 13 patients (17.6%) mainly because of neutropenia or mucositis; there was no HFS-induced dose reduction. Meanwhile, PLD therapy was discontinued mainly because of interstitial pneumonia (4 patients) and HFS (one patient).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We demonstrated the efficacy of regional cooling and oral Dex for primary prevention of PLD-induced HFS. Although future prospective studies are needed to confirm its efficacy, this combination therapy can be considered for primary prevention of HFS in ovarian cancer patients on PLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-023-07718-2","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:03:31Z","timestamp":1681895011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of regional cooling\u2009+\u2009oral dexamethasone for primary prevention of hand-foot syndrome associated with pegylated liposomal doxorubicin"],"prefix":"10.1007","volume":"31","author":[{"given":"Katsuhiko","family":"Nara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsushi","family":"Tsuruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Tojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenbun","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuyo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tappei","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Osuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"key":"7718_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0304-4157(92)90038-c","volume":"1113","author":"MC Woodle","year":"1992","unstructured":"Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113:171\u2013199. https:\/\/doi.org\/10.1016\/0304-4157(92)90038-c","journal-title":"Biochim Biophys Acta"},{"key":"7718_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1023\/a:1018907715905","volume":"10","author":"AA Gabizon","year":"1993","unstructured":"Gabizon AA, Barenholz Y, Bialer M (1993) Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 10:703\u2013708. https:\/\/doi.org\/10.1023\/a:1018907715905","journal-title":"Pharm Res"},{"key":"7718_CR3","first-page":"10","volume":"143","author":"SK Huang","year":"1993","unstructured":"Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, Friend DS (1993) Extravasation and transcytosis of liposomes in Kaposi\u2019s sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 143:10\u201314","journal-title":"Am J Pathol"},{"key":"7718_CR4","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/1097-0142(19940301)73:5<1478::aid-cncr2820730526>3.0.co;2-1","volume":"73","author":"J Vaage","year":"1994","unstructured":"Vaage J, Barber\u00e1-Guillem E, Abra R, Huang A, Working P (1994) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73:1478\u20131484. https:\/\/doi.org\/10.1002\/1097-0142(19940301)73:5%3c1478::aid-cncr2820730526%3e3.0.co;2-1","journal-title":"Cancer"},{"key":"7718_CR5","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1200\/jco.2007.13.6606","volume":"26","author":"G Ferrandina","year":"2008","unstructured":"Ferrandina G, Ludovisi M, Lorusso D et al (2008) Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 26:890\u2013896. https:\/\/doi.org\/10.1200\/jco.2007.13.6606","journal-title":"J Clin Oncol"},{"key":"7718_CR6","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/jco.2001.19.14.3312","volume":"19","author":"AN Gordon","year":"2001","unstructured":"Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312\u20133322. https:\/\/doi.org\/10.1200\/jco.2001.19.14.3312","journal-title":"J Clin Oncol"},{"key":"7718_CR7","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.3802\/jgo.2021.32.e9","volume":"32","author":"T Motohashi","year":"2021","unstructured":"Motohashi T, Yabuno A, Michimae H et al (2021) Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg\/m2 versus 40 mg\/m2 in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 trial. J Gynecol Oncol 32:e9. https:\/\/doi.org\/10.3802\/jgo.2021.32.e9","journal-title":"J Gynecol Oncol"},{"key":"7718_CR8","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1200\/jco.2006.09.6735","volume":"25","author":"DG Mutch","year":"2007","unstructured":"Mutch DG, Orlando M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811\u20132818. https:\/\/doi.org\/10.1200\/jco.2006.09.6735","journal-title":"J Clin Oncol"},{"key":"7718_CR9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2016.08.331","volume":"143","author":"M Nakayama","year":"2016","unstructured":"Nakayama M, Kobayashi H, Takahara T, Nishimura Y, Fukushima K, Yoshizawa K (2016) A comparison of overall survival with 40 and 50mg\/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: propensity score-matched analysis of real-world data. Gynecol Oncol 143:246\u2013251. https:\/\/doi.org\/10.1016\/j.ygyno.2016.08.331","journal-title":"Gynecol Oncol"},{"key":"7718_CR10","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/jco.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B et al (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302\u20131308. https:\/\/doi.org\/10.1200\/jco.2013.51.4489","journal-title":"J Clin Oncol"},{"key":"7718_CR11","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1023\/a:1008216430806","volume":"9","author":"G Berry","year":"1998","unstructured":"Berry G, Billingham M, Alderman E et al (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi\u2019s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711\u2013716. https:\/\/doi.org\/10.1023\/a:1008216430806","journal-title":"Ann Oncol"},{"key":"7718_CR12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440\u2013449. https:\/\/doi.org\/10.1093\/annonc\/mdh097","journal-title":"Ann Oncol"},{"key":"7718_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1023\/a:1008365716693","volume":"11","author":"T Safra","year":"2000","unstructured":"Safra T, Muggia F, Jeffers S et al (2000) Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2. Ann Oncol 11:1029\u20131033. https:\/\/doi.org\/10.1023\/a:1008365716693","journal-title":"Ann Oncol"},{"key":"7718_CR14","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1200\/jco.2011.38.8082","volume":"30","author":"N Colombo","year":"2012","unstructured":"Colombo N, Kutarska E, Dimopoulos M et al (2012) Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 30:3841\u20133847. https:\/\/doi.org\/10.1200\/jco.2011.38.8082","journal-title":"J Clin Oncol"},{"key":"7718_CR15","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/jco.2000.18.17.3093","volume":"18","author":"AN Gordon","year":"2000","unstructured":"Gordon AN, Granai CO, Rose PG et al (2000) Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18:3093\u20133100. https:\/\/doi.org\/10.1200\/jco.2000.18.17.3093","journal-title":"J Clin Oncol"},{"key":"7718_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/jjco\/hyn101","volume":"38","author":"N Katsumata","year":"2008","unstructured":"Katsumata N, Fujiwara Y, Kamura T et al (2008) Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with Mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a phase II study of the Japanese Gynecologic Oncology Group. Jpn J Clin Oncol 38:777\u2013785. https:\/\/doi.org\/10.1093\/jjco\/hyn101","journal-title":"Jpn J Clin Oncol"},{"key":"7718_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1006\/gyno.2000.5921","volume":"78","author":"M Markman","year":"2000","unstructured":"Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J (2000) Phase 2 trial of liposomal doxorubicin (40 mg\/m(2)) in platinum\/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78:369\u2013372. https:\/\/doi.org\/10.1006\/gyno.2000.5921","journal-title":"Gynecol Oncol"},{"key":"7718_CR18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/jco.1997.15.3.987","volume":"15","author":"FM Muggia","year":"1997","unstructured":"Muggia FM, Hainsworth JD, Jeffers S et al (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987\u2013993. https:\/\/doi.org\/10.1200\/jco.1997.15.3.987","journal-title":"J Clin Oncol"},{"key":"7718_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00520-007-0318-8","volume":"16","author":"M Hackbarth","year":"2008","unstructured":"Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J (2008) Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women\u2019s cancers. Results of a prospective study. Support Care Cancer 16:267\u2013273. https:\/\/doi.org\/10.1007\/s00520-007-0318-8","journal-title":"Support Care Cancer"},{"key":"7718_CR20","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/annonc\/mdi204","volume":"16","author":"U Jacobi","year":"2005","unstructured":"Jacobi U, Waibler E, Schulze P et al (2005) Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol 16:1210\u20131211. https:\/\/doi.org\/10.1093\/annonc\/mdi204","journal-title":"Ann Oncol"},{"key":"7718_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","volume":"26","author":"N Yokomichi","year":"2013","unstructured":"Yokomichi N, Nagasawa T, Coler-Reilly A et al (2013) Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal Doxorubicin. Hum Cell 26:8\u201318. https:\/\/doi.org\/10.1007\/s13577-012-0057-0","journal-title":"Hum Cell"},{"key":"7718_CR22","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00520-018-4054-z","volume":"26","author":"S Bun","year":"2018","unstructured":"Bun S, Yunokawa M, Tamaki Y et al (2018) Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer. Support Care Cancer 26:2161\u20132166. https:\/\/doi.org\/10.1007\/s00520-018-4054-z","journal-title":"Support Care Cancer"},{"key":"7718_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ygyno.2007.10.021","volume":"108","author":"G Mangili","year":"2008","unstructured":"Mangili G, Petrone M, Gentile C, De Marzi P, Vigan\u00f2 R, Rabaiotti E (2008) Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 108:332\u2013335. https:\/\/doi.org\/10.1016\/j.ygyno.2007.10.021","journal-title":"Gynecol Oncol"},{"key":"7718_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ygyno.2004.02.019","volume":"93","author":"KL Molpus","year":"2004","unstructured":"Molpus KL, Anderson LB, Craig CL, Puleo JG (2004) The effect of regional cooling on toxicity associated with intravenous infusion of pegylated liposomal doxorubicin in recurrent ovarian carcinoma. Gynecol Oncol 93:513\u2013516. https:\/\/doi.org\/10.1016\/j.ygyno.2004.02.019","journal-title":"Gynecol Oncol"},{"key":"7718_CR25","doi-asserted-by":"publisher","first-page":"10075","DOI":"10.12998\/wjcc.v9.i33.10075","volume":"9","author":"YF Zheng","year":"2021","unstructured":"Zheng YF, Fu X, Wang XX, Sun XJ, He XD (2021) Utility of cooling patches to prevent hand-foot syndrome caused by pegylated liposomal doxorubicin in breast cancer patients. World J Clin Cases 9:10075\u201310087. https:\/\/doi.org\/10.12998\/wjcc.v9.i33.10075","journal-title":"World J Clin Cases"},{"key":"7718_CR26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ygyno.2004.05.027","volume":"94","author":"RD Drake","year":"2004","unstructured":"Drake RD, Lin WM, King M, Farrar D, Miller DS, Coleman RL (2004) Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94:320\u2013324. https:\/\/doi.org\/10.1016\/j.ygyno.2004.05.027","journal-title":"Gynecol Oncol"},{"key":"7718_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nri.2017.1","volume":"17","author":"DW Cain","year":"2017","unstructured":"Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17:233\u2013247. https:\/\/doi.org\/10.1038\/nri.2017.1","journal-title":"Nat Rev Immunol"},{"key":"7718_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::aid-cncr13>3.0.co;2-z","volume":"89","author":"O Lyass","year":"2000","unstructured":"Lyass O, Uziely B, Ben-Yosef R et al (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037\u20131047. https:\/\/doi.org\/10.1002\/1097-0142(20000901)89:5%3c1037::aid-cncr13%3e3.0.co;2-z","journal-title":"Cancer"},{"key":"7718_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrc1318","volume":"4","author":"ST Sonis","year":"2004","unstructured":"Sonis ST (2004) The pathobiology of mucositis. Nat Rev Cancer 4:277\u2013284. https:\/\/doi.org\/10.1038\/nrc1318","journal-title":"Nat Rev Cancer"},{"key":"7718_CR30","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","volume":"18","author":"D Lorusso","year":"2007","unstructured":"Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G (2007) Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome). Ann Oncol 18:1159\u20131164. https:\/\/doi.org\/10.1093\/annonc\/mdl477","journal-title":"Ann Oncol"},{"key":"7718_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3892\/ol_00000131","volume":"1","author":"V Leonardi","year":"2010","unstructured":"Leonardi V, Palmisano V, Pepe A et al (2010) Weekly pegylated liposomal doxorubicin and paclitaxel in patients with metastatic breast carcinoma: a phase II study. Oncol Lett 1:749\u2013753. https:\/\/doi.org\/10.3892\/ol_00000131","journal-title":"Oncol Lett"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07718-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T05:08:35Z","timestamp":1684213715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07718-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["7718"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07718-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2043034\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"7 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol for the single-center retrospective observational study was implemented after being approved by the ethics committee of the Faculty of Medicine, The University of Tokyo (Approval number: 2654-(11), 3084-(7)). The institutional review board granted an opt-out recruitment approach and waived the need for obtaining written informed consent from each patient. We strictly adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"283"}}